In conclusion, we have used cell studies to provide evidence that the well-tolerated type 2 diabetes drug metformin inhibits mTOR signaling by a different mechanism than rapamycin, through suppressing BCAA and glutamine uptake. The gene discussed is MTOR; the disease is type 2 diabetes mellitus.